Rizvi N, et al. Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial. Abstract OA04.07. WCLC 2019, 7-10 september, Barcelona, Spanje.
Adjuvante behandeling pancreascarcinoom: FOLFIRINOX of gemcitabine?
mrt 2019 | Maag-darm-leveroncologie